Regeneron, Sanofi Secure EU Nod To Expand Dupixent Use In Young Children With CSU

The European Commission approved Dupixent for treating moderate-to-severe chronic spontaneous urticaria in children aged 2 to 11 years with an inadequate response to histamine-1 antihistamines. The decision expands the drug’s approved use in Europe and is a modest positive for Regeneron and Sanofi, though the article provides no sales figures or financial impact.

Analysis

The European Commission approved Dupixent for treating moderate-to-severe chronic spontaneous urticaria in children aged 2 to 11 years with an inadequate response to histamine-1 antihistamines. The decision expands the drug’s approved use in Europe and is a modest positive for Regeneron and Sanofi, though the article provides no sales figures or financial impact.